


IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Previously Presented): An N-alkoxyalkyl-N,N-dialkylamine derivative compound represented by the following general formula, or its salt, hydrate or solvate:



wherein

R¹ and R² are the same or different and represent at least one group selected from the group consisting of a hydrogen atom, a halogen atom, an unsubstituted or substituted alkyl, aryl, aralkyl, alkoxy, aryloxy, alkylthio, arylthio, alkenyl, alkenyloxy, amino, alkylsulfonyl, arylsulfonyl, carbamoyl or heterocyclic group, an unprotected or protected amino, hydroxyl or carboxyl group, a nitro group and an oxo group;

R³ and R⁴ are the same or different and represent an unsubstituted or substituted alkyl, cycloalkyl or aralkyl group;

each of mR⁵'s, mR⁶'s, nR⁷'s and nR⁸'s are the same or different and represent a hydrogen atom or an alkyl group;

the ring D represents a 5-membered heterocyclic ring containing sulfur;

m represents an integer of 1-5; and

n represents an integer of 1-6.

Claims 2-8: (Cancelled)

Claim 9 (Previously Presented): The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate or solvate of Claim 1, wherein ring D is thiophene.

Claim 10 (Previously Presented): The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate or solvate of Claim 1, wherein ring D is thiazole.

Claim 11 (Previously Presented): The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate or solvate, of Claim 1, wherein ring D is isothiazole.

Claim 12 (Previously Presented): The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate or solvate, according to Claim 1,

wherein

R^1 and R^2 are the same or different and represent at least one substituent selected from the group consisting of a hydrogen atom, a halogen atom, an unsubstituted or substituted alkyl, aryl, alkoxy, alkylthio, carbamoyl or heterocyclic group, an unprotected or protected hydroxyl or carboxyl group, and an oxo group.

Claim 13 (Previously Presented): The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate, or solvate, according to Claim 1,

wherein

R^1 and R^2 are the same or different and represent a hydrogen atom, an unsubstituted alkoxy group, or a substituted alkoxy group.

Claim 14 (Previously Presented) The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate, or solvate, wherein m is 1, and n is 2.

Claim 15 (Previously Presented) The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate, or solvate, wherein R³ is methyl or ethyl, and R⁴ is an unsubstituted alkyl, cycloalkyl or aralkyl group.

Claim 16 (Previously Presented): The N-alkoxyalkyl-N,N-dialkylamine compound or its salt, hydrate, or solvate, wherein R³ is methyl or ethyl, and R⁴ is a substituted alkyl, cycloalkyl or aralkyl group.

Claim 17 (Previously Presented): An optical isomer, geometrical isomer or tautomer of the compound of Claim 1.

Claim 18 (Cancelled):

Claim 19 (Previously Presented): An acid salt of the compound of Claim 1.

Claim 20 (Previously Presented): A base salt of the compound of Claim 1.

Claim 21 (Previously Presented): An alkali metal salt of the compound of Claim 1.

Claim 22 (Previously Presented): An alkaline earth metal salt of the compound of Claim 1.

Claim 23 (Previously Presented): A nitrogen-containing organic base salt of the compound of Claim 1.

Claim 24 (Previously Presented): A composition comprising:
the compound of Claim 1 or its salt, hydrate or solvate, and
a pharmaceutically acceptable additive or excipient.

Claim 25 (Previously Presented): The composition of Claim 23 in a form suitable for oral administration.

Claim 26 (Previously Presented): The composition of Claim 23 in the form of an aerosol.

Claim 27 (Previously Presented): The composition of Claim 23 in an injectable form.

Claim 28 (Previously Presented): The composition of Claim 23 in the form of an external preparation, ointment or suppository.

Claim 29 (Currently Amended): A method for treating a neurodegenerative disease associated with amyloid β protein (A β)-induced nerve cell death or 4-hydroxy-2-nonenal (HNE)-induced nerve cell death comprising administering to a subject in need thereof an effective amount of the compound of Claim 1.

Claim 30 (Previously Presented): A method for inducing nerve regeneration comprising administering to a subject in need thereof an effective amount of the compound of Claim 1.

Claim 31 (Previously Presented): A method for reducing hypoxia comprising administering to a subject in need thereof an effective amount of the compound of Claim 1.

Claim 32 (Currently Amended): A method of inhibiting the death of ~~for protecting~~ a nerve cell induced by amyloid β protein ($A\beta$) or induced by 4-hydroxy-2-nonenal (HNE) comprising ~~contacting~~ administering to a nerve cell ~~with~~ an effective amount of the compound of Claim 1.